Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac PCV24 in infants and children aged 2-23 months
NCT06800261Phase 1Recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sinovac PCV24 in pneumococcal infection (2 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Incidence of Adverse Reactions (0-30 days after vaccination). Started May 2025; status: recruiting.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06800261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800261.